Dupilumab in a 9-Week-Old with Netherton Syndrome Leads to Deep Symptom Control
November 2024
in “
Journal of Clinical Immunology
”
Studysummary This study reports that a 9-week-old infant with Netherton syndrome showed rapid and sustained symptom improvement, including skin microbiome normalization and developmental progress, after off-label dupilumab treatment, without adverse reactions.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on link.springer.com →